drugset / Trial / NCT04392622
d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC
Phase 1
Recruiting
40 enrolled
Stanford University
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
Non-randomizedSequentialOpen-labelSupportive care
Summary
This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect of their anti-cancer treatment.
Timeline
- Start
- 2021-02-15
- Primary completion
- 2027-08-15
- Completion
- 2028-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | d-limonene | Small molecule | 2 g | Oral |
| Subject | d-limonene | Small molecule | 4 g | Oral |
| Subject | d-limonene | Small molecule | 6 g | Oral |
| Subject | d-limonene | Small molecule | 8 g | Oral |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |
Indications
No indication recorded.